Late-onset renal variant Fabry disease with R112H mutation and mild increase in plasma globotriaosylsphingosine: a case report
Open Access
- 6 June 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1383309
Abstract
Fabry disease (FD) is an X-linked disorder resulting in a deficiency of α-galactosidase A (GLA) activity. The R112H mutation of GLA is relatively common in Japanese FD patients, characterized by a late-onset phenotype, almost normal to mild lyso-Gb3 elevation, and mild clinical symptoms, despite low GLA activity. This is due to the structural features of the R112H GLA protein. We herein report the case of a 42-year-old male patient with late-onset FD with a R112H mutation. The patient exhibited only renal involvement with no other organ damage and was successfully treated with galactosidase beta and subsequent migalastat for approximately 10 years. Especially, migalastat was clinically effective in normalizing plasma lyso-Gb3 levels and inhibiting the progression of renal damage associated with FD. Therefore, the use of migalastat in the FD patients with R112H mutation is highly recommended based on this case report.Keywords
This publication has 22 references indexed in Scilit:
- An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry diseaseMolecular Genetics and Metabolism, 2022
- In Vitro and In Vivo Amenability to Migalastat in Fabry DiseaseMolecular Therapy - Methods & Clinical Development, 2020
- Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohortJournal of Inherited Metabolic Disease, 2019
- Fabry disease in a Japanese population-molecular and biochemical characteristicsMolecular Genetics and Metabolism Reports, 2018
- The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastatGenetics in Medicine, 2017
- Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry diseaseMolecular Genetics and Metabolism Reports, 2014
- A case of Fabry nephropathy with histological features of oligonephropathyEuropean Journal of Pediatrics, 2013
- Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Elevated globotriaosylsphingosine is a hallmark of Fabry diseaseProceedings of the National Academy of Sciences, 2008
- Enzymatic Defect in Fabry's DiseaseNew England Journal of Medicine, 1967